Featured Publications
Illusory generalizability of clinical prediction models
Chekroud A, Hawrilenko M, Loho H, Bondar J, Gueorguieva R, Hasan A, Kambeitz J, Corlett P, Koutsouleris N, Krumholz H, Krystal J, Paulus M. Illusory generalizability of clinical prediction models. Science 2024, 383: 164-167. PMID: 38207039, DOI: 10.1126/science.adg8538.Peer-Reviewed Original ResearchJoint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial
Gueorguieva R, Rosenheck R, Lin H. Joint Modelling of Longitudinal Outcome and Interval-Censored Competing Risk Dropout in a Schizophrenia Clinical Trial. Journal Of The Royal Statistical Society Series A (Statistics In Society) 2011, 175: 417-433. PMID: 22468033, PMCID: PMC3315284, DOI: 10.1111/j.1467-985x.2011.00719.x.Peer-Reviewed Original ResearchLongitudinal outcomesClinical Antipsychotic TrialsQuality of lifeSchizophrenia clinical trialsStudy medicationAntipsychotic medicationClinical trialsAntipsychotic TrialsStudy participantsPhase IIntervention effectivenessMedicationsSignificant differencesSelection biasTrialsOutcomesJoint modelling approachCauses of dropoutLarge percentageParticipantsTolerabilityPatientsOutcome valuesEffect of dropoutStudy scheduleCross-trial prediction of treatment outcome in depression: a machine learning approach
Chekroud AM, Zotti RJ, Shehzad Z, Gueorguieva R, Johnson MK, Trivedi MH, Cannon TD, Krystal JH, Corlett PR. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016, 3: 243-250. PMID: 26803397, DOI: 10.1016/s2215-0366(15)00471-x.Peer-Reviewed Original ResearchConceptsTreatment outcomesTreatment groupsEscitalopram treatment groupSpecific antidepressantsPatient-reported dataSequenced Treatment AlternativesClinical trial dataIndependent clinical trialsClinical remissionSymptomatic remissionClinical trialsTreatment efficacyPatientsProspective identificationTreatment alternativesTrial dataDepressionRemissionAntidepressantsOutcomesGroupLevel 1CitalopramCohortClinicians
2021
Change in impulsivity is prospectively associated with treatment outcomes for binge-eating disorder
Boswell RG, Gueorguieva R, Grilo CM. Change in impulsivity is prospectively associated with treatment outcomes for binge-eating disorder. Psychological Medicine 2021, 53: 2789-2797. PMID: 34812713, PMCID: PMC9124732, DOI: 10.1017/s003329172100475x.Peer-Reviewed Original ResearchConceptsEating-disorder psychopathologyCognitive behavioral therapyTreatment outcomesDepression scoresPharmacological treatmentRandomized placebo-controlled clinical trialPlacebo-controlled clinical trialEfficacy of CBTBinge-eating disorderBaseline impulsivityAssociation of rapidClinical trialsTreatment groupsOverall changeDisorder psychopathologyMixed effects modelsOutcomesTreatmentBMIPatientsMeasures of impulsivityScoresPsychopathologyGeneral outcomeImpulsivityRandomized Controlled Trial of Treatments for Loss‐of‐Control Eating Following Bariatric Surgery
Grilo CM, Ivezaj V, Duffy AJ, Gueorguieva R. Randomized Controlled Trial of Treatments for Loss‐of‐Control Eating Following Bariatric Surgery. Obesity 2021, 29: 689-697. PMID: 33694287, PMCID: PMC7995173, DOI: 10.1002/oby.23124.Peer-Reviewed Original ResearchConceptsBariatric surgeryWeight lossAllied health cliniciansBariatric surgery outcomesThree-month treatmentSelf-help treatmentBariatric surgery settingsSignificant differencesControlled TrialsSurgery settingSurgery outcomesTreatment outcomesHealth cliniciansPosttreatment outcomesNon-White participantsControl eatingSurgeryTrialsOutcomesTreatmentPatientsCategorical outcomesWhite participantsAbstinenceHigher proportion
2019
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant
Wilkinson ST, Farmer C, Ballard E, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA. Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology 2019, 44: 1233-1238. PMID: 30653192, PMCID: PMC6785710, DOI: 10.1038/s41386-019-0317-8.Peer-Reviewed Original ResearchConceptsTrial of ketamineEffectiveness of midazolamRapid acting antidepressantsSaline-controlled studyPatient-level analysisEffects of ketamineImpact of midazolamClinical outcomesMidazolam dosesKetamine dosesKetamine studiesMood disordersMidazolamResponse rateModel-estimated rateKetamineTrial outcomesSalineEffect size estimatesGreater improvementEffect sizeDosesControl conditionOutcomesSimilar results
2014
Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study
Srihari VH, Tek C, Pollard J, Zimmet S, Keat J, Cahill JD, Kucukgoncu S, Walsh BC, Li F, Gueorguieva R, Levine N, Mesholam-Gately RI, Friedman-Yakoobian M, Seidman LJ, Keshavan MS, McGlashan TH, Woods SW. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry 2014, 14: 335. PMID: 25471062, PMCID: PMC4262386, DOI: 10.1186/s12888-014-0335-3.Peer-Reviewed Original ResearchConceptsEarly detectionEarly outcomesGeographic catchmentTIPS studyYounger patientsAppropriate patientsUntreated psychosisPsychosis onsetEffective treatmentCare providersPsychotic symptomsPublic education campaignsPsychotic disordersHelp-seeking behaviorSecondary aimComprehensive interventionPatientsIntervention servicesDUPEducation campaignsOutcomesSocial marketing approachPrimary aimTreatmentFES
2011
Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment
Gueorguieva R, Wu R, Donovan D, Rounsaville BJ, Couper D, Krystal JH, O’Malley S. Baseline trajectories of heavy drinking and their effects on postrandomization drinking in the COMBINE Study: empirically derived predictors of drinking outcomes during treatment. Alcohol 2011, 46: 121-131. PMID: 21925828, PMCID: PMC3266454, DOI: 10.1016/j.alcohol.2011.08.008.Peer-Reviewed Original ResearchConceptsDaily heavy drinkersFrequent heavy drinkersHeavy drinkersHeavy drinkingDrinking outcomesAlcohol-dependent patientsBehavioral intervention studyHeavy drinking trajectoriesSummary drinking measuresBaseline characteristicsActive treatmentSevere baselineCombined PharmacotherapiesWorse outcomesPharmacological interventionsCOMBINE StudyIntervention studiesPatientsTreatment factorsDrinkersOutcomesTrajectory membershipDrinking measuresTreatment effectsDrinking